vatalanib has been researched along with Neoplasms in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (56.25) | 29.6817 |
| 2010's | 13 (40.63) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Acemoglu, F; Altmann, KH; Bold, G; Boss, E; Brüggen, J; Buchdunger, E; Cozens, R; Emmenegger, R; Ferrari, S; Frei, J; Furet, P; Hofmann, F; Lang, M; Lässer, L; Manley, PW; Martiny-Baron, G; Masso, E; Mestan, J; Rösel, J; Roth, R; Schlachter, C; Sills, M; Stover, D; Traxler, P; Vetterli, W; Wietfeld, B | 1 |
| Aono, H; Ban, M; Honda, T; Inaba, T; Inoue, K; Kawashima, K; Okamoto, K; Sasabuchi, Y; Tajima, H; Takeno, Y; Yamamoto, M | 1 |
| Aono, H; Ban, M; Honda, T; Inaba, T; Inoue, K; Kawashima, K; Okamoto, K; Sasabuchi, Y; Tajima, H; Takeno, Y; Tonouchi, A; Tsuboi, T; Yamamoto, M | 1 |
| Brullo, C; Musumeci, F; Radi, M; Schenone, S | 1 |
| Adjei, AA; Croghan, GA; Dy, GK; Glockner, J; Hanson, LJ; Molina, JR; Qi, Y; Roos, MM; Tan, AD; Zhu, M | 1 |
| Adjei, AA; Lim, VS; Molina, J; Satele, D; Wang, F; Yin, J | 1 |
| Berg, W; Freeman, B; Manno, P; Sharma, S; Symanowski, J; Turner, J; Vogelzang, N | 1 |
| Antoniadis, H; Christofori, G; Crnic, I; Littlewood-Evans, A; Schomber, T; Strittmatter, K; Wood, J; Zumsteg, A | 1 |
| Chiorean, EG; Hall, SD; Jones, DR; Malireddy, S; Schneider, B; Sloop, MI; Sweeney, CJ; Waddell, MJ; Younger, AE; Yu, M | 1 |
| Beijnen, JH; Langenberg, MH; Lankheet, NA; Roodhart, JM; Rosing, H; van den Heuvel, IJ; Voest, EE; Witteveen, PO | 1 |
| Buechert, M; Chen, BL; Drevs, J; Fuxius, S; Hennig, J; Laurent, D; Lebwohl, D; Medinger, M; Mross, K; Thomas, A; Unger, C | 1 |
| Burris, H; Doss, H; Greco, FA; Hainsworth, J; Infante, J; Jones, S; Spigel, D; Thompson, D | 1 |
| Böhm-Sturm, P; Diedenhofen, M; Hoehn, M; Jikeli, JF; Ullrich, RT; Unruh, M; Vollmar, S | 1 |
| Tolcher, AW | 1 |
| Burris, HA; Jones, SF; Spigel, DR; Thompson, DF; Yardley, DA | 1 |
| Döme, B; Török, S | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Rosen, LS | 1 |
| Durrance, A; Erlich, R | 1 |
| Shiotsu, Y | 1 |
| Marmé, D | 1 |
| Cavanaugh, SX; Hammond, LA; Thomas, CR | 1 |
| Kiziltepe, T; Sasisekharan, R; Sengupta, S | 1 |
| Doherty, M | 1 |
| Haberey, M; Hess-Stumpp, H; Thierauch, KH | 1 |
| Higginson, A; Horsfield, MA; Kay, A; Laurent, D; Lee, L; Masson, E; Morgan, B; Puccio-Pick, M; Steward, WP; Thomas, AL | 1 |
| Soff, G; Zakarija, A | 1 |
| Agarwala, SS; Tawbi, H | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Denner, K; Gross, G; Gschwind, HP; Guenther, C; Jalava, T; Jost, LM; Laurent, D; Masson, E; Rottmann, A; Souppart, C; Waldmeier, F; Wang, Y | 1 |
| Jacques, C; Laurent, D; Meinhardt, G; Scott, EN; Thomas, AL | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
9 review(s) available for vatalanib and Neoplasms
| Article | Year |
|---|---|
The evolution of phase I trials in cancer medicine: a critical review of the last decade.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Phthalazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines | 2011 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
10 trial(s) available for vatalanib and Neoplasms
| Article | Year |
|---|---|
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Humans; Male; Middle Aged; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2020 |
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Phthalazines; Protein Kinase Inhibitors; Pyridines; Random Allocation; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasms; Pemetrexed; Phthalazines; Pyridines | 2009 |
A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Phthalazines; Pyridines; Transaminases; Treatment Outcome | 2010 |
Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cetuximab; Endothelial Cells; Female; Flow Cytometry; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Pyridines; Stem Cells | 2010 |
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
Topics: Administration, Oral; Drug Administration Schedule; Female; Fibroblast Growth Factor 2; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Pyridines; Vascular Endothelial Growth Factor A | 2010 |
A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Risk Assessment; Tennessee; Time Factors; Treatment Outcome; Young Adult | 2011 |
A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Young Adult | 2011 |
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Chi-Square Distribution; Chromatography, High Pressure Liquid; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Pyridines; Statistics, Nonparametric; Treatment Outcome | 2005 |
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Carbon Radioisotopes; Female; Humans; Male; Metabolic Detoxication, Phase I; Middle Aged; Molecular Structure; Neoplasms; Phthalazines; Pyridines; Tissue Distribution | 2006 |
13 other study(ies) available for vatalanib and Neoplasms
| Article | Year |
|---|---|
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
Topics: Administration, Oral; Angiogenesis Inhibitors; Aniline Compounds; Animals; Biological Availability; Cell Line; CHO Cells; Cricetinae; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Proto-Oncogene Proteins; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Transfection; Vascular Endothelial Growth Factor Receptor-1 | 2000 |
Pyridylmethylthio derivatives as VEGF inhibitors. Part 1.
Topics: Anilides; Animals; Arthritis, Experimental; Cell Line; Choroidal Neovascularization; Disease Models, Animal; Endothelial Cells; Humans; Mice; Neoplasms; Pyridines; Rats; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Pyridylmethylthio derivatives as VEGF inhibitors: part 2.
Topics: Angiogenesis Inhibitors; Animals; Arthritis, Rheumatoid; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Pyridines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2011 |
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Models, Molecular; Neoplasms; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship | 2012 |
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Disease Progression; Lymphangiogenesis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor | 2009 |
In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Magnetic Resonance Imaging; Mice; Microvessels; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Xenograft Model Antitumor Assays | 2011 |
American Society of Clinical Oncology-39th Annual Meeting. Angiogenesis. 31 May-3 June 2003, Chicago, IL, USA.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Phthalazines; Pyridines | 2003 |
Protein kinase inhibitors: novel tools in cancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Transformation, Neoplastic; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Signal Transduction | 2004 |
An image worth a thousand lives?
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzoquinones; Bibenzyls; Diagnostic Imaging; Down-Regulation; ErbB Receptors; Gefitinib; Heterocyclic Compounds, 1-Ring; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Magnetic Resonance Imaging; Molecular Probe Techniques; Mutation; Neoplasms; Phthalazines; Physiological Phenomena; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Rifabutin; Stilbenes; Tissue Distribution; Trastuzumab | 2004 |
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Extracellular Matrix; Fluorescence; Hepatocyte Growth Factor; Humans; Melanoma; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Stilbenes; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
The fight against cancer: the next round.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2004 |
PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Endothelial Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Phosphorylation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2005 |
Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Quinazolines; Vascular Endothelial Growth Factor A | 2005 |